IMDS Begins Direct U.S. Operations and Appoints President for Region

Interventional Medical Device Solutions (IMDS) has launched a direct commercial organization in the United States and chosen veteran cardiovascular executive Jason Bottiglieri to spearhead the expansion, naming him president of IMDS U.S.

“Jason’s depth of experience and proven leadership in cardiovascular medtech make him the right person to lead IMDS U.S. at this pivotal moment,” IMDS CEO Edwin Schulting said. “For more than 15 years, IMDS has worked alongside physicians to develop purpose-built PCI tools recognized for their precision and deliverability. Moving to a direct model ensures we serve physicians more directly, more responsively, and with total focus.”

IMDS products previously distributed in the United States through Biotronik will now be available directly from IMDS, supported by a U.S.-based commercial infrastructure and dedicated service teams. Customers can expect:

• Uninterrupted availability with a fully stocked U.S. warehouse
• High-touch, high-skill support from a team focused exclusively on complex coronary procedures
• Streamlined onboarding and simplified processes to keep care moving at the speed of the catheter laboratory

As part of the U.S. launch, IMDS will provide physicians full access to its portfolio of U.S. Food and Drug Administration-cleared percutaneous coronary intervention (PCI) catheters, including TrapIT, Recross, NHancerRX, MicroRX, and ShapeIT.

“Direct engagement with physicians is at the heart of what makes IMDS unique,” Bottiglieri said. “This transition reflects our commitment to greater speed, closer alignment at the point of care, and a U.S. team fully dedicated to supporting operators in complex PCI.”

Interventional Medical Device Solutions (IMDS) designs and manufactures precision-engineered solutions for complex PCI, CHIP (Complex Higher-Risk Indicated Percutaneous Coronary Intervention), and CTO (Chronic Total Occlusion) procedures. Developed in close collaboration with physicians, IMDS tools are recognized for their precision, deliverability, and quality engineering—bringing confidence to the most challenging coronary interventions.